What is HC Wainwright’s Estimate for HRMY FY2026 Earnings?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities research analysts at HC Wainwright decreased their FY2026 EPS estimates for shares of Harmony Biosciences in a research note issued on Tuesday, October 27th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $3.52 for the year, down from their prior forecast of $3.73. HC Wainwright currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.79 per share.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.32. The firm had revenue of $261.28 million for the quarter, compared to the consensus estimate of $250.77 million. Harmony Biosciences had a net margin of 18.88% and a return on equity of 20.06%. Harmony Biosciences’s quarterly revenue was up 30.3% compared to the same quarter last year. During the same period last year, the firm posted $0.92 EPS.

Several other brokerages have also commented on HRMY. WBB Securities upgraded shares of Harmony Biosciences to a “hold” rating in a research note on Friday, October 23rd. Oppenheimer reiterated an “outperform” rating on shares of Harmony Biosciences in a research report on Thursday, September 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $42.00 price objective on shares of Harmony Biosciences in a report on Thursday, October 1st. Wolfe Research began coverage on Harmony Biosciences in a report on Wednesday, August 26th. They issued an “outperform” rating and a $60.00 price objective for the company. Finally, UBS Group restated a “neutral” rating and issued a $37.00 target price on shares of Harmony Biosciences in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Harmony Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.20.

Harmony Biosciences Price Performance

NASDAQ HRMY opened at $38.50 on Thursday. Harmony Biosciences has a 52 week low of $25.90 and a 52 week high of $43.49. The company has a current ratio of 3.48, a quick ratio of 3.45 and a debt-to-equity ratio of 0.13. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 0.29 and a beta of 1.01. The company has a 50-day moving average price of $39.77 and a two-hundred day moving average price of $34.72.

Institutional Trading of Harmony Biosciences

Institutional investors have recently modified their holdings of the company. Summit Global Investments lifted its holdings in shares of Harmony Biosciences by 7.8% during the third quarter. Summit Global Investments now owns 29,143 shares of the company’s stock valued at $1,144,000 after purchasing an additional 2,109 shares during the last quarter. State of Wyoming increased its position in shares of Harmony Biosciences by 333.5% in the third quarter. State of Wyoming now owns 9,858 shares of the company’s stock worth $387,000 after acquiring an additional 7,584 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in shares of Harmony Biosciences by 66.8% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 75,882 shares of the company’s stock worth $2,979,000 after acquiring an additional 30,400 shares in the last quarter. Blueprint Investment Partners LLC purchased a new position in shares of Harmony Biosciences in the third quarter worth approximately $406,000. Finally, Blueprint Financial Advisors LLC acquired a new stake in shares of Harmony Biosciences during the third quarter valued at approximately $406,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Insider Activity at Harmony Biosciences

In other news, insider Kumar Budur sold 35,852 shares of the business’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $43.05, for a total value of $1,543,428.60. Following the sale, the insider owned 13,115 shares of the company’s stock, valued at approximately $564,600.75. The trade was a 73.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 72,406 shares of company stock valued at $3,108,520. 11.00% of the stock is currently owned by insiders.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company’s activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited.

Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy.